Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Hits Expectations

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) released its earnings results on Tuesday. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73), Briefing.com reports. The firm had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 160.27% and a negative net margin of 133.34%. The business’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.50) earnings per share.

Apellis Pharmaceuticals Stock Performance

APLS stock traded down $0.66 on Thursday, reaching $63.39. The company’s stock had a trading volume of 398,881 shares, compared to its average volume of 1,661,882. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a market capitalization of $7.51 billion, a P/E ratio of -14.21 and a beta of 0.93. The firm has a fifty day moving average of $65.25 and a two-hundred day moving average of $52.91. The company has a debt-to-equity ratio of 0.40, a current ratio of 4.29 and a quick ratio of 3.76.

Analyst Upgrades and Downgrades

Several research firms recently commented on APLS. Bank of America upgraded Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $52.00 to $85.00 in a research note on Tuesday, December 5th. Raymond James boosted their price target on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday. Needham & Company LLC boosted their price target on Apellis Pharmaceuticals from $70.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Finally, Oppenheimer upped their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $76.40.

Check Out Our Latest Report on Apellis Pharmaceuticals

Insider Buying and Selling

In related news, CAO James George Chopas sold 864 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total value of $57,723.84. Following the completion of the transaction, the chief accounting officer now directly owns 40,128 shares of the company’s stock, valued at approximately $2,680,951.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at approximately $7,006,740.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO James George Chopas sold 864 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total value of $57,723.84. Following the sale, the chief accounting officer now directly owns 40,128 shares of the company’s stock, valued at $2,680,951.68. The disclosure for this sale can be found here. Insiders sold 69,898 shares of company stock valued at $4,493,552 in the last three months. 7.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently modified their holdings of APLS. US Bancorp DE lifted its holdings in shares of Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after purchasing an additional 884 shares in the last quarter. KBC Group NV purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at $97,000. Advisor Group Holdings Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 6.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock valued at $167,000 after purchasing an additional 209 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at $175,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of Apellis Pharmaceuticals in the second quarter valued at $202,000. 90.43% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

Featured Stories

Earnings History for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.